^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

ACVR1 inhibitor

Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
02/24/2025
Initiation :
02/27/2025
Primary completion :
01/01/2033
Completion :
01/01/2034
CRP
|
Vonjo (pacritinib)
Phase 1/2
H. Lee Moffitt Cancer Center and Research Insti...
Completed
Last update posted :
03/25/2024
Initiation :
06/08/2017
Primary completion :
01/28/2022
Completion :
04/18/2022
IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C
|
sirolimus • Vonjo (pacritinib)
Phase 2
Sierra Oncology LLC - a GSK company
Completed
Last update posted :
06/19/2023
Initiation :
01/29/2016
Primary completion :
07/18/2017
Completion :
08/15/2017
CRP
|
Ojjaara (momelotinib)
Phase 1
Eisai Inc.
Completed
Last update posted :
10/14/2022
Initiation :
06/22/2008
Primary completion :
08/01/2011
Completion :
10/15/2015
BRAF
|
E6201
Phase 1/2
National University Hospital, Singapore
Recruiting
Last update posted :
08/20/2020
Initiation :
07/13/2020
Primary completion :
07/01/2023
Completion :
07/01/2023
S100A8
|
Vonjo (pacritinib)
Phase 1
Bhavana Bhatnagar
Completed
Last update posted :
01/25/2019
Initiation :
01/12/2016
Primary completion :
07/12/2018
Completion :
07/12/2018
FLT3
|
FLT3 mutation
|
cytarabine • decitabine • daunorubicin • Vonjo (pacritinib)